BHCM
SUPN icon

Brevan Howard Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Brevan Howard Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$694K Buy
14,929
+3,234
+28% +$155K 0.01% 1263
2026
Q1 		$605K Sell
11,695
-101,499
-90% -$5.17M 0.01% 1189
2025
Q4 		$5.63M Buy
113,194
+101,747
+889% +$4.95M 0.06% 215
2025
Q3 		$547K Sell
11,447
-24,658
-68% -$993K ﹤0.01% 1249
2025
Q2 		$1.14M Buy
36,105
+3,707
+11% +$119K 0.01% 1005
2025
Q1 		$1.06M Buy
32,398
+24,877
+331% +$882K 0.01% 475
2024
Q4 		$272K Buy
+7,521
New +$265K ﹤0.01% 811

Other funds holding SUPN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
NAMI
Nomura Asset Management International Philadelphia, Pennsylvania $66.6B AUM
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SIMG
Stephens Investment Management Group Houston, Texas $9.33B AUM 56.1% 1-Year Est. Return

Brevan Howard Capital Management's SUPN Position: Q2 2026 in Review

Brevan Howard Capital Management increased its Supernus Pharmaceuticals (SUPN) stake by 28% in Q2 2026, buying an estimated $155K and bringing the position to 14,929 shares worth $694K. The position accounts for 0.01% of the portfolio, ranked #1263.

Brevan Howard Capital Management first reported a position in SUPN in Q4 2024 and has held it in 7 quarters since. The position peaked at $5.63M in Q4 2025. 334 funds tracked by Wall St. Rank hold SUPN as of Q2 2026.

  • Brevan Howard Capital Management held 14,929 shares of Supernus Pharmaceuticals worth $694K as of Q2 2026.
  • Brevan Howard Capital Management bought 3,234 Supernus Pharmaceuticals shares in Q2 2026, an estimated $155K.
  • Supernus Pharmaceuticals made up 0.01% of Brevan Howard Capital Management's portfolio in Q2 2026, its #1263 holding.
  • Brevan Howard Capital Management first reported a position in Supernus Pharmaceuticals in Q4 2024 and has held it in 7 quarters since.
  • Brevan Howard Capital Management's Supernus Pharmaceuticals position peaked at $5.63M in Q4 2025.
  • 334 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q2 2026.

Based on Brevan Howard Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.